Samra Turajlić, Director of the Cancer Research UK Manchester Institute, Consultant Oncologist at The Christie and Professor at the University of Manchester, shared on LinkedIn:
“PD-1/VEGF bispecifics: exciting clinical results, but do we understand enough about the biology?
It was a pleasure to participate and present at Society for Immunotherapy of Cancer (SITC) annual meeting SITC2026 in Phoenix in this thought-provoking session
Cooperative Binding: The bispecific VEGF/PD(L)-1 inhibitor approach to cancer immunotherapy: Savior or Pretender?
The early clinical results with PD-1/VEGF bispecific antibodies are certainly encouraging and have generated considerable excitement.
But as the race to develop these agents accelerates, I believe we need to focus on a fundamental question:
Do we really understand how these agents work in patients?
I shared findings from our work studying the vascular and immune changes induced by VEGF-targeting tyrosine kinase inhibitors (TKIs) in patients. Our results challenge some of the prevailing assumptions about how effectively these agents achieve vascular normalisation and enhance anti-tumour immunity. The biological effects are more complex – and not necessarily as we might have anticipated.
These observations are particularly relevant as we move into an era of PD-1/VEGF bispecific therapies.
We need to understand not just whether these agents work, but how they work, what they change in patients on treatment, and ultimately why some patients benefit while others do not.
The race to bring these agents into clinical development is understandable. But speed alone should not define progress. A deeper understanding of their mechanisms of action and the biology underpinning clinical responses will be critical to developing and using these therapies with greater precision and confidence.
Many thanks to session co-chairs Michael Atkins and Omid Hamid for organising an excellent discussion, and to fellow speakers Rakesh Jain, John Heymach and Martin Oft Martin Oft for their valuable insights and perspectives.”
You can also read: AstraZeneca Puts $2 Billion Behind Summit’s Ivonescimab, Pairing the PD-1/VEGF Bispecific With Its ADC Portfolio
